MX2016006744A - Inhibidores de tirosina cinasa de bruton. - Google Patents
Inhibidores de tirosina cinasa de bruton.Info
- Publication number
- MX2016006744A MX2016006744A MX2016006744A MX2016006744A MX2016006744A MX 2016006744 A MX2016006744 A MX 2016006744A MX 2016006744 A MX2016006744 A MX 2016006744A MX 2016006744 A MX2016006744 A MX 2016006744A MX 2016006744 A MX2016006744 A MX 2016006744A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- btk
- bruton
- inhibitors
- tyrosine kinase
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000003844 B-cell-activation Effects 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361915582P | 2013-12-13 | 2013-12-13 | |
PCT/EP2014/077124 WO2015086642A1 (en) | 2013-12-13 | 2014-12-10 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006744A true MX2016006744A (es) | 2016-09-08 |
Family
ID=52016584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006744A MX2016006744A (es) | 2013-12-13 | 2014-12-10 | Inhibidores de tirosina cinasa de bruton. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9556150B2 (zh) |
EP (1) | EP3080099B1 (zh) |
JP (1) | JP6219523B2 (zh) |
KR (1) | KR101768402B1 (zh) |
CN (1) | CN105793252B (zh) |
CA (1) | CA2931189C (zh) |
MX (1) | MX2016006744A (zh) |
RU (1) | RU2648236C2 (zh) |
TW (1) | TW201534600A (zh) |
WO (1) | WO2015086642A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11104668B2 (en) * | 2013-12-13 | 2021-08-31 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
WO2016204261A1 (ja) * | 2015-06-17 | 2016-12-22 | 中外製薬株式会社 | アミノピラゾール誘導体 |
EP3613745B1 (en) | 2015-07-02 | 2021-09-01 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
US10871459B2 (en) | 2017-02-17 | 2020-12-22 | The Regents Of The University Of California | Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
FR2772763B1 (fr) | 1997-12-24 | 2004-01-23 | Sod Conseils Rech Applic | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
US20030236288A1 (en) | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
EP2385037A1 (en) | 2003-06-24 | 2011-11-09 | Chemtura Corporation | Fungicidal phenoxyphenylhydrazine derivatives |
BRPI0509275A (pt) | 2004-03-26 | 2007-09-04 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas de lxr(alfa) e/ou lxr(beta) e utilização dos mesmos |
DE602005022115D1 (de) | 2005-01-07 | 2010-08-12 | Pfizer Prod Inc | Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
FR2892416B1 (fr) | 2005-10-20 | 2008-06-27 | Sanofi Aventis Sa | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique |
US8629147B2 (en) | 2005-11-03 | 2014-01-14 | Chembridge Corporation | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US20080269291A1 (en) | 2005-11-18 | 2008-10-30 | Kerns Jeffrey K | Chemical Compounds |
US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
KR20100016253A (ko) | 2007-04-06 | 2010-02-12 | 노파르티스 아게 | 단백질 키나제 조절제로서의 2,6-나프티리딘 유도체 |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
CN103408533B (zh) * | 2008-06-24 | 2015-08-26 | 霍夫曼-拉罗奇有限公司 | 新型取代的吡啶-2-酮和哒嗪-3-酮 |
JP5225470B2 (ja) | 2009-08-07 | 2013-07-03 | 中外製薬株式会社 | アミノピラゾール誘導体 |
US9840515B2 (en) | 2010-12-09 | 2017-12-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Protein kinase D inhibitors |
JP5620417B2 (ja) | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
-
2014
- 2014-12-10 RU RU2016126176A patent/RU2648236C2/ru active
- 2014-12-10 EP EP14809645.6A patent/EP3080099B1/en active Active
- 2014-12-10 CA CA2931189A patent/CA2931189C/en active Active
- 2014-12-10 JP JP2016539166A patent/JP6219523B2/ja not_active Expired - Fee Related
- 2014-12-10 US US15/102,832 patent/US9556150B2/en active Active
- 2014-12-10 WO PCT/EP2014/077124 patent/WO2015086642A1/en active Application Filing
- 2014-12-10 MX MX2016006744A patent/MX2016006744A/es active IP Right Grant
- 2014-12-10 CN CN201480066841.0A patent/CN105793252B/zh active Active
- 2014-12-10 KR KR1020167018757A patent/KR101768402B1/ko active IP Right Grant
- 2014-12-11 TW TW103143358A patent/TW201534600A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW201534600A (zh) | 2015-09-16 |
CA2931189A1 (en) | 2015-06-18 |
WO2015086642A1 (en) | 2015-06-18 |
US20160311801A1 (en) | 2016-10-27 |
JP2016540022A (ja) | 2016-12-22 |
CN105793252B (zh) | 2018-01-30 |
RU2648236C2 (ru) | 2018-03-23 |
KR101768402B1 (ko) | 2017-08-14 |
JP6219523B2 (ja) | 2017-10-25 |
CA2931189C (en) | 2017-09-26 |
CN105793252A (zh) | 2016-07-20 |
KR20160097353A (ko) | 2016-08-17 |
EP3080099B1 (en) | 2018-04-11 |
EP3080099A1 (en) | 2016-10-19 |
US9556150B2 (en) | 2017-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
MX345170B (es) | Inhibidores de la tirosina-cinasa de bruton. | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
MX2014001653A (es) | Inhibidores de la tirosina-cinasa de bruton. | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
PH12015502028A1 (en) | Ido inhibitors | |
WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
EA201691514A1 (ru) | Соединения | |
MX2016006744A (es) | Inhibidores de tirosina cinasa de bruton. | |
MX370010B (es) | Inhibidores de tirosina cinasa de bruton. | |
MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
GEP20166554B (en) | Nitrogenated heterocyclic compound | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
MX352928B (es) | Compuestos de piridazina-amida. | |
PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
MX2015010466A (es) | Inhibidores de tirosina cinasa de bruton. | |
WO2014064131A3 (en) | Inhibitors of bruton's tyrosine kinase | |
MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
MX348024B (es) | Compuestos de adamantilo. | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |